BioPharmSignal logoBioPharmSignal

Biotech News

CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update

CytomX Therapeutics, Inc. (CTMX)CytomX Therapeutics, Inc.2026-06-25 13:46 ESTFDA / regulatory

- Announced Positive Data from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) EpCAM PROBODY ® ADC in Patients with Advanced Colorectal Cancer (CRC) - - FDA interactions targeted for mid-year with goal to align on potential Varseta-M registrational trial design in late line CRC -

Open original release

Related news

CTMXCytomX Therapeutics, Inc.2026-06-25 13:46 EST

CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer

CTMXCytomX Therapeutics, Inc.2026-06-25 13:46 EST

CytomX Therapeutics to Present at Upcoming June Investor Conferences

CTMXCytomX Therapeutics, Inc.2026-06-25 13:46 EST

CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs

CTMXCytomX Therapeutics, Inc.2026-06-25 13:46 EST

CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update

CTMXCytomX Therapeutics, Inc.2026-06-25 13:46 EST

CytomX Therapeutics to Present at the Jefferies London Healthcare Conference

CTMXCytomX Therapeutics, Inc.2026-06-25 13:46 EST

CytomX Therapeutics to Present at Upcoming December Investor Conferences

CTMXCytomX Therapeutics, Inc.2026-06-25 13:46 EST

CytomX Therapeutics Announces Business Update and Company Milestones for 2026

CTMXCytomX Therapeutics, Inc.2026-06-25 13:46 EST

CytomX Therapeutics to Present at Upcoming February Conferences

CTMXCytomX Therapeutics, Inc.2026-06-25 13:46 EST

CytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026

CTMXCytomX Therapeutics, Inc.2026-06-25 13:46 EST

CytomX’s Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer

View all latest news

CytomX Therapeutics, Inc.

CytomX Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

CTMXZimmer Biomet2026-07-14 12:13 EST

Zimmer Biomet Names Chintan Desai President of Asia Pacific Region

CTMXZimmer Biomet2026-07-13 12:14 EST

Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results

CTMXBMYBristol-Myers Squibb Company2026-07-13 10:59 EST

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

CTMXGSK plc2026-07-13 07:00 EST

Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer

CTMXMerck2026-07-10 19:01 EST

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

Stock data

Close
3.70 USD
Market cap
818.56M USD
Exchange
NASDAQ
Sector
Biotechnology
Location
United States